Transdermal Delivery of Enfuvirtide in a Porcine Model Using a Low-Frequency, Low-Power Ultrasound Transducer Patch

Kevin A. Snook, Robert Van Ess, Jacob Robert Werner, Ryan S. Clement, Olga M. Ocon-Grove, Jeffery Dodds, Kevin J. Ryan, Edward P. Acosta, John Zurlo, Maureen L. Mulvihill

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Ultrasound-mediated transdermal delivery is a promising parenteral administration method for large-molecule or unstable medications. This study evaluated skin health and systemic delivery when administering enfuvirtide, an injectable anti-retroviral medication, over a 1-mo period in a porcine model using a low-frequency cymbal transducer. Three groups received twice-daily treatments: (i) enfuvirtide injection control (n = 12); (ii) saline ultrasound control (n = 6); and (iii) enfuvirtide ultrasound treatment (n = 13). Ultrasound parameters were as follows: 30-min exposure, 90 mW/cm², 24–26 kHz and 15% duty cycle. No statistical difference in trans-epidermal water loss, a measure of skin health and function, was seen between ultrasound-treated and control skin sites for either saline (p = 0.50) or enfuvirtide (p = 0.29) groups. Average trough plasma concentrations of enfuvirtide were 0.6 ± 0.2 and 2.8 ± 0.8 μg/mL for ultrasound and injection, respectively. Tolerability and efficacy results indicate that chronic, low-frequency ultrasound exposure can be a practical means for transdermal delivery of medications such as enfuvirtide.

Original languageEnglish (US)
Pages (from-to)513-525
Number of pages13
JournalUltrasound in Medicine and Biology
Volume45
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

Transducers
delivery
transducers
Swine
low frequencies
health
injection
water loss
troughs
Skin
Injections
cycles
Health
enfuvirtide
molecules
Water
Therapeutics

All Science Journal Classification (ASJC) codes

  • Radiological and Ultrasound Technology
  • Biophysics
  • Acoustics and Ultrasonics

Cite this

Snook, Kevin A. ; Van Ess, Robert ; Werner, Jacob Robert ; Clement, Ryan S. ; Ocon-Grove, Olga M. ; Dodds, Jeffery ; Ryan, Kevin J. ; Acosta, Edward P. ; Zurlo, John ; Mulvihill, Maureen L. / Transdermal Delivery of Enfuvirtide in a Porcine Model Using a Low-Frequency, Low-Power Ultrasound Transducer Patch. In: Ultrasound in Medicine and Biology. 2019 ; Vol. 45, No. 2. pp. 513-525.
@article{e92cc83138a948f6ab635d8b49d18238,
title = "Transdermal Delivery of Enfuvirtide in a Porcine Model Using a Low-Frequency, Low-Power Ultrasound Transducer Patch",
abstract = "Ultrasound-mediated transdermal delivery is a promising parenteral administration method for large-molecule or unstable medications. This study evaluated skin health and systemic delivery when administering enfuvirtide, an injectable anti-retroviral medication, over a 1-mo period in a porcine model using a low-frequency cymbal transducer. Three groups received twice-daily treatments: (i) enfuvirtide injection control (n = 12); (ii) saline ultrasound control (n = 6); and (iii) enfuvirtide ultrasound treatment (n = 13). Ultrasound parameters were as follows: 30-min exposure, 90 mW/cm², 24–26 kHz and 15{\%} duty cycle. No statistical difference in trans-epidermal water loss, a measure of skin health and function, was seen between ultrasound-treated and control skin sites for either saline (p = 0.50) or enfuvirtide (p = 0.29) groups. Average trough plasma concentrations of enfuvirtide were 0.6 ± 0.2 and 2.8 ± 0.8 μg/mL for ultrasound and injection, respectively. Tolerability and efficacy results indicate that chronic, low-frequency ultrasound exposure can be a practical means for transdermal delivery of medications such as enfuvirtide.",
author = "Snook, {Kevin A.} and {Van Ess}, Robert and Werner, {Jacob Robert} and Clement, {Ryan S.} and Ocon-Grove, {Olga M.} and Jeffery Dodds and Ryan, {Kevin J.} and Acosta, {Edward P.} and John Zurlo and Mulvihill, {Maureen L.}",
year = "2019",
month = "2",
day = "1",
doi = "10.1016/j.ultrasmedbio.2018.10.003",
language = "English (US)",
volume = "45",
pages = "513--525",
journal = "Ultrasound in Medicine and Biology",
issn = "0301-5629",
publisher = "Elsevier USA",
number = "2",

}

Transdermal Delivery of Enfuvirtide in a Porcine Model Using a Low-Frequency, Low-Power Ultrasound Transducer Patch. / Snook, Kevin A.; Van Ess, Robert; Werner, Jacob Robert; Clement, Ryan S.; Ocon-Grove, Olga M.; Dodds, Jeffery; Ryan, Kevin J.; Acosta, Edward P.; Zurlo, John; Mulvihill, Maureen L.

In: Ultrasound in Medicine and Biology, Vol. 45, No. 2, 01.02.2019, p. 513-525.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Transdermal Delivery of Enfuvirtide in a Porcine Model Using a Low-Frequency, Low-Power Ultrasound Transducer Patch

AU - Snook, Kevin A.

AU - Van Ess, Robert

AU - Werner, Jacob Robert

AU - Clement, Ryan S.

AU - Ocon-Grove, Olga M.

AU - Dodds, Jeffery

AU - Ryan, Kevin J.

AU - Acosta, Edward P.

AU - Zurlo, John

AU - Mulvihill, Maureen L.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Ultrasound-mediated transdermal delivery is a promising parenteral administration method for large-molecule or unstable medications. This study evaluated skin health and systemic delivery when administering enfuvirtide, an injectable anti-retroviral medication, over a 1-mo period in a porcine model using a low-frequency cymbal transducer. Three groups received twice-daily treatments: (i) enfuvirtide injection control (n = 12); (ii) saline ultrasound control (n = 6); and (iii) enfuvirtide ultrasound treatment (n = 13). Ultrasound parameters were as follows: 30-min exposure, 90 mW/cm², 24–26 kHz and 15% duty cycle. No statistical difference in trans-epidermal water loss, a measure of skin health and function, was seen between ultrasound-treated and control skin sites for either saline (p = 0.50) or enfuvirtide (p = 0.29) groups. Average trough plasma concentrations of enfuvirtide were 0.6 ± 0.2 and 2.8 ± 0.8 μg/mL for ultrasound and injection, respectively. Tolerability and efficacy results indicate that chronic, low-frequency ultrasound exposure can be a practical means for transdermal delivery of medications such as enfuvirtide.

AB - Ultrasound-mediated transdermal delivery is a promising parenteral administration method for large-molecule or unstable medications. This study evaluated skin health and systemic delivery when administering enfuvirtide, an injectable anti-retroviral medication, over a 1-mo period in a porcine model using a low-frequency cymbal transducer. Three groups received twice-daily treatments: (i) enfuvirtide injection control (n = 12); (ii) saline ultrasound control (n = 6); and (iii) enfuvirtide ultrasound treatment (n = 13). Ultrasound parameters were as follows: 30-min exposure, 90 mW/cm², 24–26 kHz and 15% duty cycle. No statistical difference in trans-epidermal water loss, a measure of skin health and function, was seen between ultrasound-treated and control skin sites for either saline (p = 0.50) or enfuvirtide (p = 0.29) groups. Average trough plasma concentrations of enfuvirtide were 0.6 ± 0.2 and 2.8 ± 0.8 μg/mL for ultrasound and injection, respectively. Tolerability and efficacy results indicate that chronic, low-frequency ultrasound exposure can be a practical means for transdermal delivery of medications such as enfuvirtide.

UR - http://www.scopus.com/inward/record.url?scp=85058788443&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058788443&partnerID=8YFLogxK

U2 - 10.1016/j.ultrasmedbio.2018.10.003

DO - 10.1016/j.ultrasmedbio.2018.10.003

M3 - Article

C2 - 30583819

AN - SCOPUS:85058788443

VL - 45

SP - 513

EP - 525

JO - Ultrasound in Medicine and Biology

JF - Ultrasound in Medicine and Biology

SN - 0301-5629

IS - 2

ER -